Summary We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology.
Prostate cancer is the third commonest cause of male cancer deaths in the UK and 60% of patients have evidence of metastases at the time of presentation (Chisholm, 1980) . Conventional first-line therapy for patients with advanced prostatic cancer is aimed at the reduction of circulating androgen levels and suppression of androgen-dependent growth. Approximately 80% of patients treated in this way will respond, the median duration of response being 15 months (Parker et al., 1985) . All patients eventually relapse, becoming hormone insensitive, and their treatment at this stage is a difficult problem (Lancet, 1980) consisting mainly of alleviation of symptoms using analgesia, steroids, palliative single fraction radiotherapy and hemibody irradiation. An alternative approach is the reduction of residual circulating androgens which result from adrenal secretion, in an attempt to produce a further hormonal response. Such therapy includes the use of aminoglutethimide (AG). We have previously reported our experience with AG and cortisone acetate with a subjective response of almost 50% (Ponder et al., 1984) .
Detailed analysis of the endocrine changes associated with this regime showed that although there was a fall in circulating androgens from administration of glucocorticoid, no change was attributable to AG (Plowman et al., 1987; Dowsett et al., 1988) . We therefore concluded that any clinical effect of AG was not due to androgen suppression. The lack of specificity of AG and the need to use it in combination with glucocorticoids make it difficult to assign a mechanism of action with confidence. AG is an aromatase inhibitor and it has been suggested that this could be its mode of action in palliating patients with advanced prostate cancer (Worgul et al., 1983 4-OHA was given by weekly intramuscular injection in a dose of 500mg. In two patients, the dose was reduced to 250 mg fortnightly because of pain at the injection site. Patients were assessed on entry to the trial and fortnightly while on treatment. Subjective assessment was by evaluation of symptoms (pain level, analgesic requirement and performance) using the Eastern Cooperative Oncology Group (ECOG) scale (Table I) . A complete subjective response was defined as an ECOG score of 0 on 2 consecutive occasions at least 4 weeks apart and partial response as a reduction in ECOG score of > 50%. No formal objective measurements were performed in these patients although eight patients had blood taken for oestradiol, testosterone, dihydrotestosterone and androstenedione estimations pre and post treatment with 4-OHA.
Results
Nineteen patients were admitted to the trial. The age range was 58 to 83 years (average 68). All patients had previously undergone orchidectomy (13-33 months before entry: average 17) and 11 had been treated with AG and hydrocortisone (starting 4-13 months before entry: average 7). In all cases, AG and hydrocortisone was discontinued before entry. ECOG scores on entry ranged from 6 to 12.
Complete subjective response was seen in 4 (21%) and partial response in 8 (42%), giving a total subjective response of 63%. In 10 of these 12 patients, the ECOG score at 4 weeks was 4 or less. Average duration of response was 10 weeks. No patient remained in remission for more than 16 weeks.
Side effects were few: 5 patients (31%) had a transient increase in bone pain following the first injection, necessitating an increase in analgesia. We attributed this to a 'tumour flare', the mechanism of which remains obscure. Most patients complained of pain at the injection site for 24-48 hours after each injection. In two cases this necessitated dose reduction but no patient had to discontinue treatment because of side effects.
In the 8 patients on whom endocrine studies were performed, 5 showed a significant decrease in oestradiol levels. There were no changes in testosterone, dihydrotestosterone or androstenedione levels.
Discussion
Androgen deprivation has been the mainstay of treatment for advanced prostatic cancer since the pioneering studies of Huggins and Hodges (1941) on the effects of castration or oestrogen administration on men with prostate cancer. The use of anti-androgens (Scott & Schirmer, 1966) and LHRH analogues (Ahmed et al., 1985) have also been described. However, the role of oestrogens in prostatic biology is less well defined (for review see Mawhinney & Neubauer, 1979) . It has been suggested that oestrogen suppression by aromatase inhibitors may be of benefit in benign prostatic hypertrophy (Henderson et al., 1986) although there is no experimental evidence as yet to implicate oestrogens in the causation or control of the malignant prostate. Aromatase (oestrogen synthetase) is a key enzyme in the steroidogenic pathway from cholesterol to oestrogens. It mediates the conversion of androgens to oestrogens and is an enzyme complex involving NADPH, cytochrome c reductase and cytochrome p450. It is present in many tissues particularly placenta, breast, ovary, testes and adipose tissue. Its presence in prostate in vitro has been described (Stone et al., 1986) although it is still contentious (Smith et al., 1982) . Aromatisation is the last reaction in the production of oestrogens and therefore blockage of this enzyme will not cause depletion of other steroids.
Selective inhibition of aromatase may be achieved by compounds which interfere with androgen aromatisation by binding to the enzyme, or by compounds, i.e. AG, which bind to cytochrome p450 and therefore act as competitive inhibitors. 4-OHA is a potent 'suicide inhibitor' of aromatase (Brodie et al., 1981) acting both by competition with the substrate and inactivation of the enzyme causing irreversible inhibition. Clinically, 4-OHA is in clinical trial use for the treatment of post-menopausal women with advanced breast cancer (Coombes et al., 1984) .
All the patients in this study had 'end-stage' disease and we were struck by the quality of their responses, in marked contrast to those seen with AG/cortisone. Their feeling of well being was remarkable, and three of the patients were able to return to work for the duration of their remissions. Although subjective responses in such patients are open to criticism, the tumour 'flare' seen after the first injection suggests that there is a true biological response to aromatase inhibition. Additionally, the decrease in oestradiol levels observed in 5 of 8 patients in which it was measured lends support to this hypothesis. This is the first study which describes the use of a selective aromatase inhibitor in patients with advanced, hormone insensitive, prostate cancer. We have recently commenced a clinical trial using 4-OHA in patients with advanced prostate cancer, which will include detailed objective measurements and endocrine analysis during treatment. We have also commenced laboratory studies to investigate the mechanism of action of 4-OHA in prostatic biology further.
4-OHA was supplied by Ciba-Geigy Pharmaceuticals, Horsham, West Sussex.
